International nuclear medicine consensus on the clinical use of amyloid positron emission tomography in Alzheimer's disease
M Tian, C Zuo, AC Civelek, I Carrio, Y Watanabe… - Phenomics, 2023 - Springer
Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management
remaining challenging. Amyloid positron emission tomography (PET) has become …
remaining challenging. Amyloid positron emission tomography (PET) has become …
Amyloid PET imaging in clinical practice
MA Kolanko, Z Win, F Loreto, N Patel, C Carswell… - Practical …, 2020 - pn.bmj.com
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
A review of diagnostic impact of amyloid positron emission tomography imaging in clinical practice
Y Kim, P Rosenberg, E Oh - Dementia and Geriatric Cognitive …, 2018 - karger.com
Background: Molecular imaging of brain amyloid for the diagnosis of Alzheimer's disease
(AD) using positron emission tomography (PET) has been approved for use in clinical …
(AD) using positron emission tomography (PET) has been approved for use in clinical …
Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice
Positron emission tomography (PET) of brain amyloid is a technology that has been
approved by Food and Drug Administration and European Medical Agency, but its clinical …
approved by Food and Drug Administration and European Medical Agency, but its clinical …
The who, when, why, and how of PET amyloid imaging in management of Alzheimer's disease—Review of literature and interesting images
Amyloid imaging using positron emission tomography (PET) has an emerging role in the
management of Alzheimer's disease (AD). The basis of this imaging is grounded on the fact …
management of Alzheimer's disease (AD). The basis of this imaging is grounded on the fact …
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's …
KA Johnson, S Minoshima, NI Bohnen… - Alzheimer's & …, 2013 - Elsevier
Positron emission tomography (PET) of brain amyloid β is a technology that is becoming
more available, but its clinical utility in medical practice requires careful definition. To …
more available, but its clinical utility in medical practice requires careful definition. To …
Canadian consensus guidelines on use of amyloid imaging in Canada: update and future directions from the specialized task force on amyloid imaging in Canada
Positron emission tomography (PET) imaging of brain amyloid beta is now clinically
available in several countries including the United States and the United Kingdom, but not …
available in several countries including the United States and the United Kingdom, but not …
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial
Importance Amyloid positron emission tomography (PET) allows the direct assessment of
amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this …
amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this …
A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being …
Background: Amyloid PET (aPET) imaging could improve patient outcomes in clinical
practice, but the extent of impact needs quantification. Objective: To provide an aggregated …
practice, but the extent of impact needs quantification. Objective: To provide an aggregated …
相关搜索
- amyloid pet nuclear medicine
- amyloid pet use criteria
- alzheimer's disease clinical use
- nuclear medicine use criteria
- consensus guidelines amyloid imaging
- clinical practice amyloid imaging
- amyloid pet molecular imaging
- amyloid pet alzheimer's association
- nuclear medicine molecular imaging
- nuclear medicine alzheimer's association